Institute of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, 324 Jingwu Road, Jinan, 250021, PR China.
Institute of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, 324 Jingwu Road, Jinan, 250021, PR China; Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong University, 324 Jingwu Road, Jinan, 250021, PR China.
Biomed Pharmacother. 2019 May;113:108779. doi: 10.1016/j.biopha.2019.108779. Epub 2019 Mar 16.
Lung cancer remains the leading cause of oncological death. There is an urgent need to discover new molecular targets and to develop new treatments. One of the UDP-glucuronosyltransferases (UGTs) family, UGT1A3, is highly expressed in lung adenocarcinoma (LUAD), and is associated with poor prognosis. Its inhibitor, hesperetin, may play an important role in anticancer therapy. The purpose of this study was to investigate the role of UGT1A3 in the progression of lung adenocarcinoma and to explore the value of its inhibitor hesperetin in the treatment of LUAD. Hesperetin suppressed lung adenocarcinoma cell proliferation and migration. The combination treatment of hesperetin with platinum suppressed tumor progression more significantly, especially compared with single drug treatment. UGT1A3 is an important prognostic factor for LUAD, and hesperetin can synergize platinum drugs by inhibiting UGT1A3 and increasing levels of reactive oxygen species (ROS).
肺癌仍然是肿瘤死亡的主要原因。迫切需要发现新的分子靶点并开发新的治疗方法。UDP-葡萄糖醛酸基转移酶 (UGTs) 家族之一的 UGT1A3 在肺腺癌 (LUAD) 中高度表达，与预后不良有关。其抑制剂橙皮苷可能在抗癌治疗中发挥重要作用。本研究旨在探讨 UGT1A3 在肺腺癌进展中的作用，并探讨其抑制剂橙皮苷在 LUAD 治疗中的价值。橙皮苷抑制肺腺癌细胞的增殖和迁移。橙皮苷与铂类药物联合治疗可更显著地抑制肿瘤进展，尤其是与单一药物治疗相比。UGT1A3 是 LUAD 的一个重要预后因素，橙皮苷通过抑制 UGT1A3 和增加活性氧 (ROS) 水平与铂类药物协同作用。
